Ironwood Pharmaceuticals Inc (IRWD):企業の財務・戦略的SWOT分析

◆英語タイトル:Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15507
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ironwood Pharmaceuticals Inc (IRWD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ironwood Pharmaceuticals Inc (Ironwood) is a biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. Its major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc Key Recent Developments

Mar 11,2019 Ironwood Capital Group Opens in Milwaukee
Feb 13,2019 Ironwood Pharmaceuticals provides fourth quarter and full year 2018 investor update
Jan 28,2019 Ironwood announces filing of Form 10 registration statement in connection with planned business separation
Jan 24,2019 Ironwood Pharmaceuticals initiates phase 1 trial of IW6463

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ironwood Pharmaceuticals Inc – Key Facts
Ironwood Pharmaceuticals Inc – Key Employees
Ironwood Pharmaceuticals Inc – Key Employee Biographies
Ironwood Pharmaceuticals Inc – Major Products and Services
Ironwood Pharmaceuticals Inc – History
Ironwood Pharmaceuticals Inc – Company Statement
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ironwood Pharmaceuticals Inc – Business Description
Ironwood Pharmaceuticals Inc – Corporate Strategy
Ironwood Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Ironwood Pharmaceuticals Inc – Strengths
Ironwood Pharmaceuticals Inc – Weaknesses
Ironwood Pharmaceuticals Inc – Opportunities
Ironwood Pharmaceuticals Inc – Threats
Ironwood Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2019: Ironwood Capital Group Opens in Milwaukee
Feb 13, 2019: Ironwood Pharmaceuticals provides fourth quarter and full year 2018 investor update
Jan 28, 2019: Ironwood announces filing of Form 10 registration statement in connection with planned business separation
Jan 24, 2019: Ironwood Pharmaceuticals initiates phase 1 trial of IW6463
Jan 24, 2019: Ironwood Pharmaceuticals announces board of directors for Ironwood and Cyclerion, effective following separation
Jan 23, 2019: Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW6463 the First CNSpenetrant sGC Stimulator to Enter Clinical Trials
Jan 06, 2019: Ironwood Pharmaceuticals appoints Michael Shetzline, M.D., Ph.D. as chief medical officer
Jan 04, 2019: Ironwood Pharmaceuticals announces chief executive officers to lead Ironwood and Cyclerion, effective upon upcoming separation
Jan 03, 2019: Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESSÂ linaclotide Patent Litigation
Oct 08, 2018: Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ironwood Pharmaceuticals Inc, Key Facts
Ironwood Pharmaceuticals Inc, Key Employees
Ironwood Pharmaceuticals Inc, Key Employee Biographies
Ironwood Pharmaceuticals Inc, Major Products and Services
Ironwood Pharmaceuticals Inc, History
Ironwood Pharmaceuticals Inc, Subsidiaries
Ironwood Pharmaceuticals Inc, Key Competitors
Ironwood Pharmaceuticals Inc, Ratios based on current share price
Ironwood Pharmaceuticals Inc, Annual Ratios
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...1)
Ironwood Pharmaceuticals Inc, Interim Ratios
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ironwood Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Ironwood Pharmaceuticals Inc, Ratio Charts
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TomTom NV (TOM2):企業の財務・戦略的SWOT分析
    TomTom NV (TOM2) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Glomac Berhad:企業の戦略・SWOT・財務情報
    Glomac Berhad - Strategy, SWOT and Corporate Finance Report Summary Glomac Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • CNH Industrial NV:企業の戦略・SWOT・財務情報
    CNH Industrial NV - Strategy, SWOT and Corporate Finance Report Summary CNH Industrial NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Carnarvon Petroleum Ltd (CVN):石油・ガス:M&Aディール及び事業提携情報
    Summary Carnarvon Petroleum Ltd (Carnarvon Petroleum) is an oil and gas company that acquires, explores, and develops oil and gas properties. The company's projects comprise Cerberus and the Phoenix project. It has assets in Barrow sub-basin, Perth basin, and Roebuck basin. Carnarvon Petroleum's Pho …
  • GETECH Group plc (GTC):企業の財務・戦略的SWOT分析
    Summary Getech Group Plc (Getech) is an oil and gas service company that offers geological and geophysical services. The company’s services include regional reports, globe, commissions and global gravity and magnetic data solutions. Its in-house specialties comprise airborne geophysics, potential fi …
  • Watchstone Group plc (WTG):企業の財務・戦略的SWOT分析
    Summary Watchstone Group plc (Watchstone), formerly Quindell Plc, is a technology company that offers services such as software; consulting and technology enabled outsourcing services. The company provide solutions such as Hubio, pt Health, ingenie, InnoCare, QuoteSupermarket, and others. It provide …
  • Bioverativ Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Dil Ltd (506414):企業の財務・戦略的SWOT分析
    Summary Dil Ltd (Dil), formerly Duphar-Interfran Ltd, is a developer of medicinal and pharmaceutical products. The company offers products in the areas such as biotechnology, environmental solutions, pharmaceuticals, and vitamins. It also offers services such as health and wellness, entertainment, e …
  • Beautiful Brands International, LLC:企業の戦略・SWOT・財務分析
    Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report Summary Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Multiplicom NV-医療機器分野:企業M&A・提携分析
    Summary Multiplicom NV (Multiplicom) is a molecular diagnostic company that develops, manufactures and markets genetic test kits. The company offers onco genetics, human genetics and prenatal genetics products. Its human genetics products are used for cancer genetics, genetic disorders and neurologi …
  • Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company which discovers and develops therapeutics for the treatment of solid tumors and blood cancers. Its lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogene …
  • BoneSupport AB:医療機器:M&Aディール及び事業提携情報
    Summary BoneSupport AB (BoneSupport), a subsidiary of Bonesupport Holding AB, is a orthobiologics company that develops, manufactures and markets injectable bioceramic bone graft substitutes for the treatment of fragility fractures caused by osteoporosis; bone voids and gaps caused by trauma; infect …
  • PTC Inc.:企業の戦略・SWOT・財務情報
    PTC Inc. - Strategy, SWOT and Corporate Finance Report Summary PTC Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Global Ports Holding PLC (GPH):企業の財務・戦略的SWOT分析
    Global Ports Holding PLC (GPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • RUAG Holding AG:企業の戦略・SWOT・財務情報
    RUAG Holding AG - Strategy, SWOT and Corporate Finance Report Summary RUAG Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Electronic Arts Inc.:企業の戦略・SWOT・財務分析
    Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report Summary Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Amerisafe Inc:企業の戦略・SWOT・財務分析
    Amerisafe Inc - Strategy, SWOT and Corporate Finance Report Summary Amerisafe Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Energias de Portugal S.A:企業の戦略・SWOT・財務分析
    Energias de Portugal S.A - Strategy, SWOT and Corporate Finance Report Summary Energias de Portugal S.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Energizer Holdings, Inc.:企業の戦略・SWOT・財務情報
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AGCO Corporation (AGCO):企業の財務・戦略的SWOT分析
    AGCO Corporation (AGCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆